Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody
AssigneeJanssen Biotech, Inc.
InventorsCarrie Brodmerkel, Mark Curran, Linda Greenbaum, Shannon Telesco
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for treating Crohn's Disease with an antibody that binds NKG2D. In particular, it relates to dosing regimens for administration of an anti-NGK2D antibody. It also relates to methods of selecting patients for treatment with an anti-NKG2D antibody.
Claims17
A method of treating a human patient with Crohn's disease, the method comprising administering to the human patient a safe and effective amount of an anti-NKG2D antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequences set forth in SEQ ID NO:
- 3, 4 and 5, respectively and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequences set forth in SEQ ID NO:
- 6, 7, and 8, respectively, wherein the method comprises at least one administration cycle, wherein for each of the at least one cycle, the anti-NKG2D antibody is administered as follows:
- (a) one dose of 400 mg anti-NKG2D antibody and (b) at least one dose of 200 mg anti-NKG2D antibody.
A method of treating a human patient with Crohn's disease, the method comprising the steps of:
- (a) determining whether the human patient has a SNP in an NKG2D receptor gene or MICB gene by obtaining a biological sample from the human patient and performing a genotyping assay on the biological sample;
- (b) administering an anti-NKG2D receptor antibody if the patient has the SNP, wherein the anti-NKG2D antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequences set forth in SEQ ID NO:
- 3, 4 and 5, respectively and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequences set forth in SEQ ID NO:
- 6, 7, and 8, respectively.
Dependencies are inferred from the claim text.